Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC‐Netherlands Cancer Registry linked data with 20 years of follow‐up
- 21 October 2016
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 176 (1), 65-75
- https://doi.org/10.1111/bjh.14379
Abstract
The survival of patients diagnosed with Hodgkin lymphoma (HL) has improved from 70% to 90% in clinical trials. However, population-based data has shown lower survival. In this study, clinical trial data were linked with cancer registry to identify trial and non-trial participants and differences in overall survival and associated factors were assessed. In 1986–2004, 27% of HL patients aged 15–70 years participated in clinical trials. Compared to non-trial participants, trial participants were younger (median age, 31 vs. 34 years), had staging registered more accurately and had an 8% higher 20-year survival rate (73% vs. 65%). After adjusting for baseline differences, no differences in survival (hazard ratio = 0·96, 95% confidence interval 0·82–1·12), or in subgroup analysis according to stage, remained. Over time, increased administration of chemotherapy in combination with radiotherapy, together with the decreased use of radiotherapy alone was observed among the trial population. This trend was later followed in non-trial participants, coinciding with a similar ‘take-up’ in survival. The observed superior survival among patients with HL treated in clinical trials can be largely explained by the differences in baseline characteristics, particularly younger age. High trial participation rate and centralized expertise facilitates the implementation of trial findings to real-world practice.Keywords
Funding Information
- European Organisation for Research and Treatment of Cancer
- European Organisation for Research and Treatment of Cancer
This publication has 32 references indexed in Scilit:
- A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern eraBlood, 2012
- How we treat elderly patients with Hodgkin lymphomaCurrent Opinion in Oncology, 2011
- Survival after Hodgkin lymphomaCancer, 2009
- In Defense of Pharmacoepidemiology — Embracing the Yin and Yang of Drug ResearchNew England Journal of Medicine, 2007
- Hodgkin's Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the German Hodgkin's Study GroupJournal of Clinical Oncology, 2005
- International rules for multiple primary cancers (ICD-0 third edition)European Journal Of Cancer Prevention, 2005
- Standard cancer patient population for age standardising survival ratiosEuropean Journal Of Cancer, 2004
- Involved-Field Radiotherapy for Advanced Hodgkin's LymphomaNew England Journal of Medicine, 2003
- Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”Journal of Clinical Epidemiology, 2001
- Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.Journal of Clinical Oncology, 1993